The science of testosterone: How the HPG axis works and why it matters for treatment

Introduction: Why the mechanism matters

Most men looking into testosterone want one thing: higher testosterone. But how testosterone is raised matters, because different medications act on different points in the body's hormonal signaling chain, with different consequences for fertility and for the system's own function.

Understanding the hypothalamic-pituitary-gonadal (HPG) axis makes those differences legible. This is educational physiology. It isn't medical advice or a recommendation of any specific treatment.

The HPG axis: A three-level signaling chain

Testosterone production is governed by a cascade with three levels.

The hypothalamus produces gonadotropin-releasing hormone (GnRH) in a pulsatile pattern, releasing it at intervals rather than continuously. The pulsatile nature is important: continuous GnRH exposure suppresses the pituitary rather than stimulating it.

The anterior pituitary responds to GnRH by releasing two gonadotropins. Luteinizing hormone (LH) signals the Leydig cells in the testes to produce testosterone. Follicle-stimulating hormone (FSH) acts on the Sertoli cells, which support sperm production.

The testes carry out the work: Leydig cells synthesize testosterone, and Sertoli cells maintain the environment needed for spermatogenesis.

The whole system is regulated by negative feedback. Testosterone and its metabolite estradiol signal back to the hypothalamus and pituitary, moderating GnRH, LH, and FSH output to maintain balance.

Where the system can fall short

Low testosterone can originate at different levels of this axis, and the distinction is clinically meaningful.

In primary hypogonadism, the testes themselves aren't producing enough testosterone despite adequate signaling. LH and FSH are typically elevated as the pituitary works harder, while testosterone remains low.

In secondary hypogonadism, the signal is the problem. The hypothalamus or pituitary isn't producing adequate GnRH, LH, or FSH, so the testes aren't being stimulated. This pattern is commonly discussed in the context of age-related change and obesity-related low testosterone.

Mixed patterns involving both reduced signaling and reduced testicular response also occur.

Distinguishing between these requires blood testing interpreted by a clinician. Luvo's evaluation is based on your health history and reported symptoms; Luvo does not provide lab testing, so any testing is arranged through your own physician.

How each medication acts on the axis

The three medications in Luvo's Testosterone Program intervene at different points.

Testosterone medication acts at the end of the chain, supplying the hormone directly. Because the body detects the added testosterone, upstream signaling (GnRH, LH, FSH) is suppressed, which reduces the testes' own activity.

Enclomiphene acts at the top of the chain. By blocking estrogen's negative feedback at the hypothalamus, it increases GnRH output, which raises LH and FSH and in turn supports endogenous testosterone production. This depends on the testes being able to respond to increased stimulation.

Gonadorelin acts in the middle of the chain, providing GnRH signaling to the pituitary to support LH and FSH output. It is used for HPG axis support and endogenous testosterone support, including in the context of fertility preservation alongside testosterone therapy.

Some of these are compounded or prescribed off-label, and compounded medications are not FDA-approved. A licensed provider explains this before prescribing.

Why this matters for the conversation with your provider

Because the medications act at different levels, the appropriate choice depends on where in the axis the shortfall lies, along with your health history, your fertility intentions, and your goals. That's a clinical determination, made with a licensed provider, and it can be revisited over time.

Explore Luvo's Testosterone Program, or the individual options: testosterone, enclomiphene, and gonadorelin.